Researchers create mycobacteria with kill switches to improve TB vaccine safety

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with “kill switches” that can be triggered to stop the bacteria after they activate an immune response.

Filament Health Nets $2.1M in Revenue in 2023 | Psychedelic Invest

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) has recently shared its financial achievements for both the final quarter and the entire fiscal year

April 4, 2024

Cell therapy startup ArsenalBio raises $325M as it runs early solid tumor trials

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 5, 2024

Amylyx to voluntarily withdraw ALS drug Relyvrio after Phase 3 fail, will lay off around 70%

Amylyx announced Thursday morning that it will pull its ALS drug Relyvrio from the US and Canadian markets. The decision comes as Amylyx will also

April 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.